TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03171649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETRAINER-S1
Description: It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy
Study: NCT03909789

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant based bioequivalent Nitrate supplementation
Description: The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02700906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
Study: NCT03109496

Intervention type: OTHER
Intervention: Collection of body fluids/swabs
Description: Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.

Intervention type: OTHER
Intervention: Collection of body fluids/swabs
Description: Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
Study: NCT01875653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)
Description: Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous PBMCs in GM-CSF (MC)
Description: Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
Study: NCT00755053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole, vaginal ovule
Description: Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole, vaginal tablet
Description: Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
Study: NCT02527811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
Study: NCT00403520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental 1
Description: Drug: Donepezil Hydrochloride 10 mg orally for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Drug: Placebo Matching placebo orally for 12 months
Study: NCT01099722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutiform
Description: inhaler 2 puffs bd daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbohaler
Description: 2 puffs bd daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbohaler
Description: 2 puffs bd daily
Study: NCT00571493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
Description: All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells.
Study: NCT03835195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Disease Management Program
Description: The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Process
Description: The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
Study: NCT03159429

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nasal breathing rehabilitation
Description: The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
Study: NCT01874899

Intervention type: DEVICE
Intervention: RestoreSensor Neurostimulation

Intervention type: DEVICE
Intervention: RestoreSensor Neurostimulation
Study: NCT02124837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park walk during lunch break

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation during lunch break
Study: NCT01672580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to vitamin use
Description: Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to vitamin use
Description: Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure to vitamin use
Description: Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to water chlorination
Description: Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to water chlorination
Description: Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure to water chlorination
Description: Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high in-degree
Description: Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high in-degree
Description: Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nominated by random
Description: Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nominated by random
Description: Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual
Study: NCT04467684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 100 mg
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 200 mg
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 400 mg
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 800 mg
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 1,000 mg
Description: Single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Color and size matched placebo
Study: NCT01941810

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin supplement
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04111380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and nab-paclitaxel
Description: Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
Study: NCT00456222

Intervention type: BEHAVIORAL
Intervention: Disrupting or changing the timing or the duration of sleep
Description: Disrupting or changing the timing or the duration of sleep

Intervention type: BEHAVIORAL
Intervention: Disrupting or changing the timing or the duration of sleep
Description: Disrupting or changing the timing or the duration of sleep
Study: NCT01187355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)
Description: Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: renu fresh Multi-Purpose Solution (MPS)
Description: Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses
Description: Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
Study: NCT00389610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreas vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreas vaccine
Description: Given intradermally
Study: NCT01499940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
Study: NCT02199184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02691507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram Skin Barrier Emulsion
Description: EpiCeram Skin Barrier Emulsion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Product 1% Colloidal Oatmeal Balm
Description: Experimental Product 1% Colloidal Oatmeal Balm
Study: NCT03354195

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.
Description: All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.
Description: All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.
Description: All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)
Study: NCT01948596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Study: NCT03743168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent stretching protocol
Description: Intermittent stretching protocol of five sets of 1 minute and15 second rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous stretch
Description: 2 minutes continuous stretch
Study: NCT03788512

Intervention type: OTHER
Intervention: observational only- no intervention
Description: observational only- no intervention
Study: NCT01526863

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HA egg
Description: Daily dose of HA egg or placebo for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HA egg
Description: Daily dose of HA egg or placebo for 6 months
Study: NCT01615484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™
Description: After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STEEN Solution™
Description: This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
Study: NCT01352715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/zidovudine
Description: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Description: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
Study: NCT02293148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 500 mg
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
Study: NCT01352715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.